Macquarie Group’s Kiora Pharmaceuticals KPRX Stock Holding History

Macquarie Group’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5	Closed	-$27K	–	2270
2017 Q4	$27K	Buy	+5	New	+$30.9K	﹤0.01%	2193

Other funds holding KPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Macquarie Group's KPRX Position: Q1 2018 in Review

Macquarie Group sold out of Kiora Pharmaceuticals (KPRX) in Q1 2018, closing a stake of 5 shares — an estimated $27K sold.

Macquarie Group first reported a position in KPRX in Q4 2017 and held it in 1 quarter. The position peaked at $27K in Q4 2017. 16 funds tracked by Wall St. Rank hold KPRX as of Q1 2018.

Macquarie Group reported no remaining Kiora Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 5 Kiora Pharmaceuticals shares in Q1 2018, an estimated $27K.
Macquarie Group first reported a position in Kiora Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Macquarie Group's Kiora Pharmaceuticals position peaked at $27K in Q4 2017.
16 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.